Targeting dormant leukaemia cells
Nature
May 12, 2008
A new role for a protein involved in leukaemia is described in Nature this week; the research demonstrates its potential as a therapeutic target to eradicate dormant leukaemia-initiating cells.
The promyelocytic leukaemia protein (PML) tumour suppressor is known to be involved in the development of some forms of leukaemia. Pier Paolo Pandolfi and colleagues identify a new and unexpected role for PML in the maintenance of both haematopoietic stem cells and leukaemia-initiating cells. They demonstrate, in mice, that targeting the protein with arsenic trioxide eliminates the cancer-initiating cells, thought to be resistant to chemotherapy and other therapies.
The team believes that their results present a new pharmacological approach to target cells that are missed by other therapies and therefore lead to disease relapse.
doi: 10.1038/nature07016
Research highlights
-
Jul 1
Criminology: Predicting police enforcement bias in major US citiesNature Human Behaviour
-
Jul 1
Evolution: Pandas gave bamboo the thumbs up at least six million years agoScientific Reports
-
Jul 1
Space health: The path of most resistance could help limit bone loss during spaceflightScientific Reports
-
Jun 30
Microbiology: Transmission of gastrointestinal viruses in salivaNature
-
Jun 30
Genomics: Gray wolf genome hints at dual ancestry of dogsNature
-
Jun 30
Evolution: Hawks learn on the fly to swoop up before perchingNature